August 31, 2014 7:44 AM ET

Healthcare Equipment and Supplies

Company Overview of Bausch & Lomb Incorporated

Company Overview

Bausch & Lomb Incorporated produces eye care products. The company offers contact and hydrophobic acrylic intraocular lenses; contact lens care, dry eye, allergy/redness relief, pharmaceutical, and surgical products; and eye vitamins and vision accessories. It also offers contract manufacturing services for sterile and non-sterile solutions, suspensions, ointments, gels, creams, nasals, and injectables. The company was formerly known as Bausch & Lomb Optical Company and changed its name to Bausch & Lomb Incorporated in March 1960. Bausch & Lomb Incorporated was founded in 1853 and is based in Rochester, New York. It has additional offices in Argentina, Australia, Austria, Belgium, Bulgaria, ...

1400 North Goodman Street

Rochester, NY 14609

United States

Founded in 1853

Phone:

585-338-6000

Fax:

585-338-6896

Key Executives for Bausch & Lomb Incorporated

President and Chief Financial Officer
Age: 53
President of Asia-Pacific
Age: 69
Corporate Vice President and Global President of Pharmaceuticals Business
Age: 46
Corporate Vice President and President of Latin America Operations
Global President of Vision Care Business
Age: 58
Compensation as of Fiscal Year 2014.

Bausch & Lomb Incorporated Key Developments

Nicox to Co-Promote Latanoprostene Bunod in US with Bausch + Lomb

Nicox SA announced its decision to exercise rights to co-promote latanoprostene bunod in the US with Bausch + Lomb. According to the terms of a licensing agreement signed by the two companies in 2010, Nicox retains the possibility to co-promote latanoprostene bunod in the US.

Bausch & Lomb Inc. Wins $16.69 Million Federal Contract

Bausch & Lomb Inc. won a $16,689,720.96 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Chicago, for PreserVision Areds 2 Formula and PreserVision Areds Lutein.

Bausch + Lomb's VICTUS(R) Femtosecond Laser Platform Receives 510(K) Clearance from FDA for Lens Fragmentation Procedure

Valeant Pharmaceuticals International Inc. announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS(R) Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery. The fragmentation procedure, which follows a capsulotomy, uses the femtosecond laser to split the cataractous lens into sections. This is followed by phacoemulsification for cataract removal. The VICTUS platform offers a number of different lens fragmentation patterns depending on the cataract grade and user preference.

Similar Private Companies By Industry

Company Name Region
Entellus Medical, Inc. United States
VMBC, LLC United States
RespCare, Inc. United States
IncisionTech United States
Aseptico, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bausch & Lomb Incorporated, please visit www.bausch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.